tetano
Editor, Senior Moderator
Antivir Ther. 2013 Aug 15. doi: 10.3851/IMP2672. [Epub ahead of print]
Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir.
Cao RY, Xiao JH, Cao B, Li S, Kumaki Y, Zhong W.
Source
National Engineering Research Center for Strategic Drugs, Beijing Institute of Pharmacology and Toxicology, Beijing, PR China.
Abstract
BACKGROUND:
A novel reassortant avian-origin influenza A (H7N9) virus was isolated from respiratory specimens obtained from three patients and was identified as H7N9 in China. The antiviral agents are required to treat the patients with the avian influenza H7N9 virus infection.
METHODS:
In this study, we assessed the antiviral potential of oseltamivir, peramivir, favipiravir (T-705), amantadine and remantadine against novel reassortant avian-origin influenza H7N9 virus in vitro.
RESULTS:
All three avian influenza H7N9 virus strains were sensitive to oseltamivir, peramivir and favipiravir (T-705), but resistant to amantadine and rimantadine.
CONCLUSIONS:
These properties might be therapeutically advantageous if they are considered for possible clinical use to treat H7N9 virus infections.
PMID:
23948557
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23948557
Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir.
Cao RY, Xiao JH, Cao B, Li S, Kumaki Y, Zhong W.
Source
National Engineering Research Center for Strategic Drugs, Beijing Institute of Pharmacology and Toxicology, Beijing, PR China.
Abstract
BACKGROUND:
A novel reassortant avian-origin influenza A (H7N9) virus was isolated from respiratory specimens obtained from three patients and was identified as H7N9 in China. The antiviral agents are required to treat the patients with the avian influenza H7N9 virus infection.
METHODS:
In this study, we assessed the antiviral potential of oseltamivir, peramivir, favipiravir (T-705), amantadine and remantadine against novel reassortant avian-origin influenza H7N9 virus in vitro.
RESULTS:
All three avian influenza H7N9 virus strains were sensitive to oseltamivir, peramivir and favipiravir (T-705), but resistant to amantadine and rimantadine.
CONCLUSIONS:
These properties might be therapeutically advantageous if they are considered for possible clinical use to treat H7N9 virus infections.
PMID:
23948557
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23948557